Merck withdraws European filing for Erbitux in NSCLC
“We are disappointed that we have not been able to…
18 September 2012 | By Merck
“We are disappointed that we have not been able to move forward with the filing..."
List view / Grid view
“We are disappointed that we have not been able to…
18 September 2012 | By Merck
“We are disappointed that we have not been able to move forward with the filing..."
For the Treatment of Patients with Newly Diagnosed or Previously-Treated…
25 March 2011 | By Bristol-Myers Squibb Company
For the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer...